Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go
Pharm Stat
.
2011 Jan-Feb;10(1):1-2.
doi: 10.1002/pst.402.
Authors
Steven Snapinn
1
,
Qi Jiang
Affiliation
1
Amgen, Department of Global Biostatistics and Epidemiology, Thousand Oaks, CA 91320, USA. ssnapinn@amgen.com
PMID:
20029938
DOI:
10.1002/pst.402
No abstract available
MeSH terms
Clinical Trials as Topic / statistics & numerical data*
Humans
Research Design
Statistics as Topic / methods*